ROKIT Healthcare (KOSDAQ 376900), a leading AI-driven hyper-personalized organ regeneration platform company, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference (JPM Week), held from January 12 to 15 in San Francisco. The company aims to solidify its global market presence through various high-level engagements during the event.

During JPM Week, ROKIT Healthcare plans to accelerate its investor communications and expand its partnership network, with a particular focus on North America. Notably, the company has been selected to deliver a corporate presentation at Biotech Showcase™ 2026, which runs concurrently with the J.P. Morgan conference. ROKIT will present its core technological capabilities and global commercialization strategies to an international audience of investors and biopharma executives.

Biotech Showcase is a premier investor conference where private biotechnology companies connect with investors and pharmaceutical giants. The 2026 event is expected to draw more than 1,200 investors managing upwards of $400 billion in capital.

Throughout the week, ROKIT Healthcare will engage in a multi-faceted business development strategy, including:

▶Expanding global distribution and hospital networks.

▶Discussing strategic partnerships and joint development opportunities.

▶Conducting Investor Relations (IR) activities targeting overseas institutional investors.

Through these efforts, the company intends to reinforce its growth engine by bridging the gap between "technical validation," "business expansion," and "capital markets."

"In early January, San Francisco becomes the world’s most vibrant stage where global healthcare capital and innovation converge," said a representative from ROKIT Healthcare. "We are committed to elevating our global standing during this week and accelerating the delivery of tangible collaborative results."